We can’t show the full text here under this license.
JAMA network open···
Changes in Food Buying Habits After Starting a Glucagon-Like Peptide-1 Receptor Agonist
Updated
Related papers
May '25
Glucagon-like peptide-1 drugs vs. sodium/glucose transporter inhibitors for reducing kidney failure and death in type 2 diabetes patients with kidney disease
top 5% journal
cited by 6 papers
comparative study
Mar '24
Real-World Effects of Weekly GLP-1 Medicines Compared to DPP-4 Inhibitors on Blood Sugar and Weight in Type 2 Diabetes
top 30% journal
cited by 8 papers
observational study
May '21
Weight Loss and Maintenance Linked to How Glucagon-Like Peptide 1 Receptor Agonists Work
top 20% journal
cited by 246 papers
research support, non-u.s. gov't
Oct '24
Glucagon-like peptide-1 receptor drugs and pancreatic cancer risk studied using real-world data
top 1% journal
cited by 38 papers
journal article
May '21
Glucagon-like peptide-1 drugs and their effects on insulin, glucagon, and stomach emptying in Japanese people with type 2 diabetes
top 20% journal
cited by 36 papers
observational study
Mar '24
Glucagon-like peptide-1 drugs and the risk of liver problems in people with fatty liver disease cirrhosis and type 2 diabetes
top 5% journal
cited by 59 papers
research support, n.i.h., extramural
Jun '25
Glucagon-like Peptide-1 Medicines and Dementia Risk in People with Type 2 Diabetes Over Time
top 10% journal
cited by 6 papers
journal article
Nov '25
Medical Use of GLP-1 and GLP-1/GIP Receptor Drugs Explained by How They Work
top 20% journal
cited by 6 papers
journal article
May '22
Link between diabetes drugs that activate GLP-1 receptors and bile duct diseases in type 2 diabetes patients
top 20% journal
cited by 15 papers
research support, non-u.s. gov't
GLP-1 Therapies